The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead's Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
A Phase IIb/III study sponsored by NIAID is being stopped early after an interim analysis indicated that injected cabotegravir provided better protection than Gilead's Truvada.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
In an announcement over the weekend, the British drugmaker said the FDA had cited manufacturing issues in its complete response letter for cabotegravir and rilpivirine.
An HIV drug candidate developed under a joint venture between GlaxoSmithKline (NYSE:GSK) and Japanese pharmaceutical company Shionogi is showing promise as a contender to take on a blockbuster drug from rival Merck (NYSE:MRK). Initial phase 3 clinical trial results for dolutegravir show the GSK-Shionogi compound matches Merck’s HIV treatment raltegravir. But dolutegravir’s advantage will be […]
An HIV/AIDS treatment developed by GlaxoSmithKline (NYSE:GSK) is now being studied with Siemens (NYSE:SI) to develop companion diagnostics that doctors can use to select patients appropriate for the treatment. The partnership with ViiV Healthcare, GSK’s AIDS drug joint venture with Pfizer (NYSE:PFE), will study the drug Selzentry in a phase 3 study comparing it to […]
Generic competition for GlaxoSmithKline (NYSE:GSK) AIDS drug Epzicom is on its way around the world, if not the United States. Yet. The U.S. Food and Drug Administration has given tentative approval for a formulation of the drug made by Cipla, a pharmaceutical company based in Mumbai, India. The tentative approval comes under expedited review from […]
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
GlaxoSmithKline‘s (NYSE:GSK) HIV treatment combivir will soon face its first competition from a generic drug. Teva Pharmaceutical Industries (NASDAQ:TEVA) has received U.S. Food and Drug Administration approval on its application to market a generic version of combivir. Combivir is a combination drug that pairs azidothymidine, also known as AZT, with another antiviral, lamivudine. The combination […]